Unknown

Dataset Information

0

Use of Spironolactone in SARS-CoV-2 ARDS Patients.

ABSTRACT:

SUBMITTER: Dumanlı GY 

PROVIDER: S-EPMC7279869 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Use of Spironolactone in SARS-CoV-2 ARDS Patients.

Dumanlı Güleren Yartaş GY   Dilken Olcay O   Ürkmez Seval S  

Turkish journal of anaesthesiology and reanimation 20200430 3

Similar Datasets

Unknown Defibrotide Therapy for SARS-CoV-2 ARDS.
| S-EPMC8993696 | biostudies-literature
Unknown SARS-CoV-2 detection in the lower respiratory tract of invasively ventilated ARDS patients.
| S-EPMC7562762 | biostudies-literature
Unknown Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury.
| S-EPMC7916525 | biostudies-literature
Unknown Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications.
| S-EPMC8861575 | biostudies-literature
Unknown COVID-19-The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection.
| S-EPMC7830835 | biostudies-literature
Unknown Spironolactone use and oocyte maturation in patients undergoing controlled ovarian hyperstimulation.
| S-EPMC11339222 | biostudies-literature
Unknown Biodistribution and serologic response in SARS-CoV-2 induced ARDS: A cohort study.
| S-EPMC7685466 | biostudies-literature
Unknown SARS-CoV-2 antibody immunoassays in serial samples reveal earlier seroconversion in acutely ill COVID-19 patients developing ARDS.
| S-EPMC8118560 | biostudies-literature
Unknown Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
| S-EPMC7298698 | biostudies-literature
Unknown SARS-CoV-2-Induced ARDS Associates with MDSC Expansion, Lymphocyte Dysfunction, and Arginine Shortage.
| S-EPMC7775842 | biostudies-literature